Regulatory Strategy11 min read
Recent FDA approvals show expanding scientific and regulatory flexibility for novel antimicrobials. The harder precedent remains commercial: narrow labels, stewardship-constrained use, and fragile launch economics continue to threaten otherwise valuable products.
Regulatory Strategy18 min read
FDA's RMAT approval record reveals several repeatable evidentiary models, from paired-lesion randomization to natural history controls and response-based accelerated approval. The pathway is most valuable when enhanced FDA interaction is used to resolve product-specific uncertainty rather than to avoid it.
Oncology15 min read
Individualized mRNA vaccines have progressed from demonstrations of immune activation to randomized efficacy testing in resected cancer. Intismeran autogene leads the field, while autogene cevumeran and several early-stage platforms are testing whether the model can extend across tumors and development settings.
Cell and Gene Therapy16 min read
Solid-tumor CAR-T has crossed the regulatory threshold, but the clinical evidence remains uneven. One randomized program shows a real but modest survival gain, while several early programs produce striking responses in small, selected cohorts without yet establishing durable population-level benefit.
FDA Approvals14 min read
Adquey adds another nonsteroidal topical option for mild-to-moderate atopic dermatitis. Its approval is especially notable for how FDA evaluated two positive Japanese pivotal trials, supportive multinational evidence, and an incomplete U.S. Phase 3 study.
Drug Development18 min read
The first FDA approval confirms that a heterobifunctional degrader can complete the clinical and regulatory pathway. The broader pipeline and its growing record of discontinuations show why target degradation alone is not enough.
FDA Policy24 min read
Single-trial approvals were already a substantial part of FDA practice before the 2026 policy debate. The revised draft guidance points toward wider use of one-trial programs, but not toward a lower evidentiary burden in every setting.
Regulatory Strategy18 min read
The lessons from failed Alzheimer's programs become clearer when read against the therapies that secured FDA approval. The resulting record shows that regulatory success depends on the complete alignment of mechanism, disease stage, exposure, biomarker strategy, clinical outcomes, safety, and approval pathway.
Research11 min read
A research brief on how HIV treatment, long-acting prevention, and NRTI geroscience are converging around the broader question of healthspan.
Cardiovascular Market Landscape9 min read
Newly branded hypertension therapies are moving the category beyond traditional add-on sequencing. Baxfendy, Tryvio, lorundrostat, and zilebesiran illustrate an emerging split between approved oral options, pending class competition, and longer-horizon outcome-driven development.
Cardiometabolic14 min read
Hyperlipidemia care in 2026 is moving from a statin-centered sequence toward earlier combination therapy, injectable and RNA-based options, and risk-stratified treatment of LDL-C, triglycerides, familial syndromes, and Lp(a). The future pipeline is broad, but most late-stage innovation still depends on outcomes data and label-specific regulatory interpretation.
Longevity14 min read
Longevity medicine is increasingly built around repurposed metabolic, immunologic, and senolytic interventions, but no drug is approved to treat aging itself. The evidence base remains strongest for disease-risk modification and preclinical lifespan signals, not for demonstrated human lifespan extension.